Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2022-10-31
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heart Failure Evaluation Study
NCT05583513
Daily Ambulatory Remote Monitoring System For Post-Dischage Management Of ADHF
NCT03072693
Community Surveillance of Congestive Heart Failure
NCT00005517
Clinical Study of Active Intervention in High-risk HFpEF Patients
NCT06532019
Predictors and Outcomes of In-hospital HFpEF in AMI Patients
NCT03351179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
REDUCE
Standard care
Standard care
Standard clinical care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard care
Standard clinical care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Congestion on chest X-ray
* Rales on chest auscultation
* Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale)
* Elevated jugular venous pressure
* NT-proBNP ≥300 pg/mL (Patients with AF: NT-proBNP ≥900 pg/mL)
* Heart failure hospitalization that requires the treatment of a minimum single dose of 40 mg of i.v. furosemide (or equivalent i.v loop diuretics)
* Ambulatory patients
Exclusion Criteria
* Cardiac mechanical support implantation like LVAD
* Life expectancy less than 1 year due to underlying significant comorbidities like metastatic cancer or end-stage COPD
* Haemodynamically severe uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study.
* End stage renal failure or eGFR \<15 mL/min/1.73m2 as measured during index hospitalization or requiring dialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Bryan Ping Yen YAN
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bryan Yan
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Chinese University of Hong Kong
Shatin, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022.245
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.